Brief: Ryvu Therapeutics Q3 Net Loss At 24.7 Million Zlotys
Nov 20 (Reuters) - Ryvu Therapeutics SA RVU.WA: Q3 NET LOSS AT 24.7 MILLION ZLOTYS Q3 OPERATING REVENUE 61.9 MILLION ZLOTYS Q3 OPERATING LOSS 44.6 MILLION ZLOTYS Source text: ID:nEM8b8NlJa Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; 48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys